SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending as the community rallies around its active development team, which is focused on building utility and staking options. Community members are excited about upcoming burns and contests, and many believe the coin is undervalued. The conversation highlights the coin's strong community and dedication to breaking into the top trending spot.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid discussions about potential market expansions and community members evaluating its future prospects relative to other meme coins. Some traders are weighing SHIB against competitors, while others are pointing to technical indicators and expressing general bullish sentiment. Chatter about smaller cap coins that could see similar parabolic rallies to DOGE.X and SHIB.X is also present.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-native meme coin launched via the Runes protocol, inheriting Bitcoin's decentralized ethos and aiming to onboard retail investors to the Bitcoin ecosystem. The community emphasizes its fair launch and potential to surpass other meme coins like DOGE by leveraging Bitcoin's network security; discussions also highlight the backing from $CBLO.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid community chatter about a potential licensing deal and speculation around upcoming data releases. Discussions revolve around the company's strategic direction and the potential impact of ongoing clinical trials for their lung cancer drug. Bullish investors are highlighting insider buying and the drug's potential to compete with existing treatments.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

SOL is trending as the community discusses potential institutional investment and the possibility of a Solana ETF. Broader conversations revolve around staking opportunities and the ecosystem's growth, particularly within the meme coin space. Some traders are noting bullish technical patterns and anticipating further price appreciation.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as the crypto community rallies behind Dog of Bitcoin ($DOG), viewing it as more than just a memecoin but as a movement rooted in Bitcoin's principles. Supporters believe $DOG embodies a fair, decentralized, and community-driven approach, positioning it as a potential successor to Dogecoin and a significant player in the Bitcoin Layer-2 ecosystem.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to news of a land sale boosting its NAV, with the community focusing on its low float and potential for a significant upward move. Chatter suggests the stock is undervalued, with some anticipating a potential squeeze and rapid price increase if key resistance levels are broken. Investors are closely watching for a breakout and considering potential entry points.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul C. Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest ($PINS) is trending as the community discusses its potential S&P 500 inclusion and AI-driven growth strategies, with some highlighting user growth and engagement while others express concerns about ad pricing and competition. Speculation around potential acquisition by larger tech players like Meta or Apple is also circulating. Overall sentiment seems cautiously optimistic about Pinterest's long-term prospects amid discussions of valuation and growth potential within the broader social media and e-commerce landscape.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as community members highlight its unique protocol that rewards holders with $SOL.X based on trading volume, promoting it as a DeFi savings account. The community is rallying behind the token's resilience and potential for long-term growth, emphasizing its community-led nature and new partnerships. Discussions also highlight the shift towards web 4.0 protocols rewarding user belief rather than hype, positioning $IMG.X as a leading example on the Solana blockchain.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

IDYA is trending due to positive Phase 2 data and a successful FDA meeting regarding its uveal melanoma treatment, darovasertib, potentially leading to accelerated approval. Community members are focused on the drug's efficacy and potential for eye preservation, as well as upcoming presentations. Analysts are also weighing in with positive ratings and price target adjustments, citing a promising pipeline beyond its lead asset.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth

ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.

Barclays has initiated coverage of Incyte (INCY) with an ‘Overweight’ rating and a $90 price target on Friday.The price target implies an over 20% upside to the stock’s closing price on Thursday.&nbsp;Shares of the company traded about 0.4% higher on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INCY">INCY</a> trended in the ‘bullish’ territory, accompanied by ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1332/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_2_26_04_PM_png_30d60d7ced.webp" alt="INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits" width="1332" height="126"><figcaption>INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits</figcaption></figure>The firm said that it sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.It believes the pivotal data for Tafasitamab in diffuse large B-cell lymphoma and the mid-stage data for Povorcitinib in chronic spontaneous urticaria patients provide the next legs of growth for Incyte.Earlier this week, Incyte said during its second-quarter earnings that it now expects late-stage data from the study evaluating Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma by the second half of 2025. Incyte is now focusing on its development pipeline as its cancer drug, Jakafi, nears patent expiration.“Continued progress and diversification of our portfolio, including advancements with povorcitinib and mutCALR, are strengthening the foundation for sustainable, long-term growth,” CEO Bill Meury said.Jakafi net revenue came in at $764 million in the second quarter of the year, marking a growth of 8% year-on-year, and accounting for about 63% of the company’s total revenue in the quarter of $1.216 billion, which surpassed Wall Street expectations. &nbsp;For the full year, the company is eyeing revenue of $3 billion to $3.5 billion from Jakafi.Another important drug from the company is its Opzelura cream, used to treat nonsegmental vitiligo, which brought in revenues of $164 million in the second quarter, marking a growth of 35% year-on-year.Overall, for the second quarter, the company reported an adjusted and diluted earnings per share of $1.57, compared to a loss per share of $1.82 reported in the corresponding period of 2024.According to data from Koyfin, 11 of 27 analysts covering the stock rate it ‘Buy’ or higher, while 15 rate it ‘Hold’, and just one rates it a ‘Sell’. The average price target on the stock is $79.87, representing an upside of about 6% from the current price.The stock is up by over 9% this year and by about 17% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pheton-holdings-dismisses-rumors-of-acquisition-by-gilead/chrEENyRdRR">Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer 

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.

Equity

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.


Why Incyte (INCY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of +12.95% and +5.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

INCY
Incyte Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INCY News

INCY Incyte Corp.